

DOCKET NO.: CELL-0285/PAC018-USW01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Robert John Watson, et al.

Confirmation No.: 3692

Application No.: 10/505,234

Group Art Unit: 1615

Filing Date: December 9, 2004

Examiner: Not Yet Assigned

For: PIPERIDIN-4-YL UREA DERIVATIVES AND RELATED COMPOUNDS AS
CHEMOKINE RECEPTOR INHIBITORS FOR THE TREATMENT OF
INFLAMMATORY DISEASES

DATE OF DEPOSIT:

March 23, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE UNITED STATES PATENT AND
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,
VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).



In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **1 – 11 and 14 - 24** listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers **12 and 13** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for

DOCKET NO.: CELL-0285/PAC018-USW01 - 3 -

PATENT


which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: *March 22, 2005*



Jane E. Ingles
Registration No. 48,444

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW



| | | | |
|---|----|--|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | | Docket No. CELL-0285/ PAC018-USw01 | Application No. 10/505,234 |
| | | Applicant Robert John Watson, et al. | |
| | | Filing Date December 9, 2004 | Group 1615 |
| | | Confirmation No. 3692 | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | 1 | Bodor, N., "Novel approaches in prodrug design," <i>Alfred Benson Symposium</i> , 1982, 17, 156-177 | |
| | 2 | Bousquet, J., et al., "Eosinophilic inflammation in asthma," <i>N. Eng. J. Med.</i> , 1990, 323, 1033-1039 | |
| | 3 | Kay, A.B., et al., "Eosinophils and neutrophils," <i>Br. Med. Bull.</i> , 1992, 48, 51-64 | |
| | 4 | Luster, A.D., "Chemokines – chemotactic cytokines that mediate inflammation," <i>New Eng. J. Med.</i> , 1998, 338, 436-445 | |
| | 5 | Qin, S., et al., "The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions," <i>J. clin. Invest.</i> , 1998, 101(4), 746-754 | |
| | 6 | Rollins, B.J., "Chemokines," <i>Blood</i> , 1997, 90(3), 909-928 | |
| | 7 | Saunders, J., et al., "Opportunities for novel therapeutic agents acting at chemokine receptors," <i>Drug Discovery Today</i> , 1999, 4(2), 80-92 | |
| | 8 | Schwarz, M.K., et al., "Interfering with chemokine networks – the hope for new therapeutics," <i>Curr. Opin. Chem. Biol.</i> , 1999, 3, 407-417 | |
| | 9 | Singh, G., et al., "Prodrug approach in new drug design and development," <i>J. Sci. Ind. Res.</i> , 1996, 55, 497-510 | |
| | 10 | Sørensen, T.L., et al., "Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients," <i>J. Clin. Invest.</i> , 1999, 103, 807-815 | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|----|--|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | | Docket No. CELL-0285/ PAC018-USw01 | Application No. 10/505,234 |
| | | Applicant Robert John Watson, et al. | |
| | | Filing Date December 9, 2004 | Group 1615 |
| | | Confirmation No. 3692 | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | 11 | Wells, T.N.C., et al., "Definition, function and pathophysiological significance of chemokine receptors," <i>Trends Pharmacol Sci.</i> , 1998 , 19, 376-380 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| EXAMINER | | DATE CONSIDERED | |

| | | |
|---|--|-------------------------------|
| Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office | Docket No. CELL-0285/ PAC018-USw01 | Application No. 10/505,234 |
| | Applicant Robert John Watson, et al. | |
| | Filing Date December 9, 2004 | Group 1615 |
| | Confirmation No. 3692 | |

U. S. PATENT DOCUMENTS

| Examiner Initial | | Document No. | Date | Name | Class | Subclass |
|------------------|----|--------------|----------|---------------|-------|----------|
| | 12 | 3,424,761 | 01/28/69 | Grover | 260 | 326.3 |
| | 13 | 6,329,395 B1 | 12/11/01 | Dugar, et al. | 514 | 329 |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | | Document No. | Date | Country | Translation | |
|------------------|----|----------------|----------|---------|-------------|----|
| | | | | | YES | NO |
| | 14 | WO 00/23419 A1 | 04/27/00 | PCT | | |
| | 15 | WO 00/76511 A1 | 12/21/00 | PCT | | |
| | 16 | WO 00/76512 A1 | 12/21/00 | PCT | | |
| | 17 | WO 00/76513 A1 | 12/21/00 | PCT | | |
| | 18 | WO 00/76514 A1 | 12/21/00 | PCT | | |
| | 19 | WO 00/76972 A1 | 12/21/00 | PCT | | |
| | 20 | WO 00/76973 A1 | 12/21/00 | PCT | | |
| | 21 | WO 01/14333 A1 | 03/01/01 | PCT | | |
| | 22 | WO 02/16353 A1 | 02/28/02 | PCT | | |
| | 23 | 0 625 507 B1 | 07/23/97 | EP | | |
| | 24 | 0 916 668 A1 | 05/19/99 | EP | | |
| | | | | | | |

| | |
|-----------------|------------------------|
| EXAMINER | DATE CONSIDERED |
|-----------------|------------------------|